SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as retail investors draw comparisons to the 2021 short squeeze, with some hoping it will mirror the recent volatility in $BYND. Community members discuss call options, potential buybacks, and the possibility of a gamma squeeze. Despite the positive price action, some remain skeptical, citing weak fundamentals and high volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer's stock is trending due to a revised revenue outlook, citing design win upgrades impacting delivery schedules and shifting some revenue to the next quarter. Despite reiterating a strong fiscal year forecast, the community is actively debating the impact of the news, management's credibility, and potential trading strategies given the volatility. Some investors express frustration with the company's leadership and consistency in meeting expectations, while others view the dip as a buying opportunity amidst robust AI demand.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as it joins the S&P 100, sparking community discussion about the company finally breaking the $100 mark. Bullish sentiment is fueled by strong financials, autonomous vehicle developments, and a potential for further gains, although some traders express frustration with past price action. Many are closely watching if Uber can maintain momentum and solidify its position.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors anticipate the upcoming GTC conference, where new products and partnerships are expected to be revealed, possibly driving the stock toward $190. Bullish sentiment is fueled by optimism surrounding potential deals and positive economic data, while some traders are wary of potential pullbacks and China-related headwinds. The community is actively discussing potential price movements and technical analysis, with strong opinions on both bullish and bearish scenarios.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its strategic partnership with Palantir to enhance enterprise AI capabilities and its potential role in the growing AI sector, particularly regarding data centers and fiber optic infrastructure. Community members are also anticipating upcoming earnings and speculating on potential acquisitions. The broader discussion revolves around Lumen's transformation and its position in the evolving tech landscape.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid speculation that the Trump administration might take an equity stake in quantum computing firms, fueling significant community discussion and trading volume. Despite some contradictory reports and denials of ongoing negotiations, chatter persists around the potential for government investment to boost the sector and counter China's quantum initiatives. Traders are actively debating the validity of news sources and the potential impact on the stock's future.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending following positive Phase 2 trial results for its Parkinson's drug, showing safety and target engagement. The community is buzzing about potential analyst upgrades and buyout scenarios, particularly by Sanofi given their existing relationship. Discussions also involve the drug's broader applicability and market potential beyond Parkinson's.

Bleichroeder Acquisition Corp. I is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Bleichroeder Acquisition Corp. I - Ordinary Shares - Class A

Bleichroeder Acquisition Corp I

Bleichroeder Acquisition Corp I (BACQ) is trending due to increased interest following bullish sentiment from Citron Research, highlighting the company's merger with Merlin Labs, an AI autonomous flight technology firm, and existing government contracts. The community is actively discussing the potential for significant gains, particularly focusing on the undervalued rights and the company's partnerships within the aerospace and defense sectors. Some are drawing comparisons to other AI-related SPACs and anticipating a substantial price increase.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending amid news of a partnership with Anthropic to integrate AI models into its software, seen as a boost to enterprise AI capabilities. The community is discussing IBM's leadership in quantum computing and AI, as well as its potential for long-term growth, though some remain cautious. Recent analyst ratings and price target adjustments are also contributing to the conversation around the stock.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid speculation surrounding a potential sale or strategic partnership, possibly involving major players like SpaceX or Amazon, following comments from the chairman about a potential multi-billion dollar deal. Community discussions revolve around the valuation of Globalstar's spectrum and assets, comparing it to recent transactions in the satellite communications sector, and the potential impact of Apple's involvement and the company's expansion in IoT.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251014866366/en/AstraZeneca-unveils-expanded-manufacturing-facility-in-Texas">invested</a> $445 million to expand the facility, it said. The unveiling <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-announces-4.5-billion-dollar-investment-in-virginia/ch67yQKR31I">follows</a> the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia. &nbsp;The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.The facility supplies the drug to more than 50 countries worldwide. <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a> said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AZN stock is up by 29% this year and by about 8% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 

Equity

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 


Drugmaker AstraZeneca (AZN) on Thursday said that it will invest $4.5 billion in a new manufacturing facility in Virginia amid President Donald Trump’s push to move pharmaceutical manufacturing to American soil.The investment is $500 million more than initially planned and is intended to support the enhanced manufacturing capability of a broader range of medicines, including weight management, metabolic, and cancer technologies, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251009456597/en/AstraZeneca-plans-to-increase-investment-and-scope-of-its-Virginia-manufacturing-facility-to-%244.5-billion-creating-3600-new-jobs">said.</a>The new facility will be located at Rivanna Futures in Albemarle County, and the company expects the facility to create 600 skilled jobs and an additional 3000 jobs to support the facility’s construction. The construction will start immediately, and the facility is expected to be operational in the next four to five years, the company added.The new announcement is part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then. AstraZeneca CEO Pascal Soriot on Thursday noted that the investment in Virginia is the largest in the company’s history.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume dropped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:996/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_1_46_59_PM_png_5e85c683cb.webp" alt="AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="996" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.Last month, AstraZeneca <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-plans-ordinary-share-listing-in-us/chDub9CR376">announced</a> that it plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq. The move is part of the company’s efforts to expand its access to capital, it had said, while noting that the U.S. has the world’s largest and most liquid public markets by capitalization.AZN stock is up by 31% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-intends-to-launch-longer-range-model-y-variant-in-china/ch67xJOR315">Tesla Reportedly Intends To Launch A Longer Range Model Y Variant In China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Announces $4.5B Investment In Virginia 

The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company. 

AstraZeneca (AZN) on Friday launched an at-home delivery service for its Flumist influenza vaccine ahead of the upcoming flu season.Flumist is a vaccine that is sprayed into the nose to help protect against influenza in people aged two through 49 years. However, it may not prevent influenza in everyone who gets vaccinated, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250815310613/en/FLUMIST-Influenza-Vaccine-Live-Intranasal-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery">stated</a>.The vaccine was initially approved by the U.S. Food and Drug Administration in 2003. It can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals aged 2-17 years.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Adults aged 18 and older can visit the Flumist website and click to order, following which they will be directed to complete a medical screening questionnaire. These submissions will then be reviewed by a licensed healthcare provider with ASPN Pharmacies, an independent online specialty pharmacy, to determine eligibility.Once eligibility is confirmed and insurance verified, the vaccine will be prescribed and shipped to the consumer’s home by Polaris Pharmacy Services, a specialty pharmacy, in temperature-controlled packages.The vaccine will be delivered with clear administration instructions, storage guidance, and disposal instructions, AstraZeneca said. Once received, the vaccine should be stored in the refrigerator until use. The home delivery service will be available only in 34 states for the upcoming flu season due to local pharmacy laws, the company said. However, AstraZeneca is eyeing making the service available across all 48 contiguous states in future seasons.Flumist, meanwhile, will continue to be available in doctors’ offices and pharmacies for administration by healthcare professionals across the nation, the company added.AZN stock is up by 20% this year but down by about 8% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/big-short-investor-michael-burry-cuts-stake-in-estee-lauder/chsPoDFRdfW">‘Big Short’ Investor Michael Burry Cuts Stake In Estee Lauder By A Whopping 25% – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine

Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with placebo at 12 weeks in a late-stage study evaluating the drug in uncontrolled or treatment-resistant hypertension.Nasdaq-listed shares of the company traded 0.3% higher at the time of writing.The reduction in systolic blood pressure was both statistically significant and clinically meaningful, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html">said</a> in a statement. Baxdrostat was generally well tolerated with a favourable safety profile in the trial, where patients with uncontrolled or treatment-resistant hypertension received the investigational drug or placebo on top of standard of care.According to <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a>, there are 1.3 billion people worldwide living with hypertension, a medical condition characterised by consistently high blood pressure levels, which can, over time, damage blood vessels and vital organs. While uncontrolled hypertension persists despite treatment with two or more medications, resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications.A key contributor to hypertension is aldosterone, a hormone that increases blood pressure by promoting sodium and water retention. Baxdrostat is an oral, small-molecule investigational drug that inhibits an enzyme responsible for the synthesis of aldosterone in the adrenal gland.AstraZeneca acquired Baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash is payable to former CinCor shareholders upon the submission of a new drug application either in the U.S. or Europe.AstraZeneca said on Monday that the data from the late-stage trial will be shared with regulatory authorities around the world, but did not detail when it will seek approval for the drug from the U.S. Food and Drug Administration.Baxdrostat is currently being investigated in clinical trials for hypertension, primary aldosteronism, chronic kidney disease, and the prevention of heart failure in high-risk hypertensive patients.On Stocktwits, retail sentiment around AstraZeneca is unchanged within the ‘neutral’ territory over the past 24 hours, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1366/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_9_51_14_AM_png_716900ba11.webp" alt="AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>AZN stock was up by 9% this year but down by about 9% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gsk-seeks-fda-approval-for-rsv-vaccine-in-more-adults/ch8ByXHR5Vp">GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React

The reduction in systolic blood pressure in the trial was both statistically significant and clinically meaningful, the company said in a statement.

QQMG
Invesco ESG NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest QQMG News

QQMGInvesco ESG NASDAQ 100 ETF